Overexpression of activin-A and -B in malignant mesothelioma - Attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth

Experimental Cell Research

Volumn 332, Issue 1, 2015, Pages 102-115

  Tamminen, Jenni A ^a,b   Yin, Miao ^a,b   Rönty, Mikko ^a,c   Sutinen, Eva ^a,c   Pasternack, Arja ^a,c   Ritvos, Olli ^a,c   Myllärniemi, Marjukka ^a,b,c   Koli, Katri ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Activin; Invasive growth; Mesothelioma

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN LIKE KINASE 3; ACTIVIN LIKE KINASE 4; ACTIVIN LIKE KINASE 7; ACTIVIN RECEPTOR; ACTIVIN RECEPTOR 2B; CELL SURFACE RECEPTOR; FOLLISTATIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPID; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR TYPE II-A; ACVR1C PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CAPILLARY ENDOTHELIUM; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALIGNANT MESOTHELIOMA; MESOTHELIOMA CELL LINE; MIDDLE AGED; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; CELL MOTION; FEMALE; GENE EXPRESSION; GENETICS; LUNG TUMOR; MALE; MESOTHELIOMA; METABOLISM; PATHOLOGY; TUMOR INVASION;

ACTIVIN RECEPTORS, TYPE I; ACTIVIN RECEPTORS, TYPE II; ACTIVINS; AGED; CELL MOVEMENT; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MESOTHELIOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; SMAD3 PROTEIN;

EID: 84924612803     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.12.010     Document Type: Article

References (48)

1. Mossman B.T., Shukla A., Heintz N.H., Verschraegen C.F., Thomas A., Hassan R. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am. J. Pathol. 2013, 182:1065-1077.
2. Huuskonen M.S., Rantanen J. Finnish Institute of Occupational Health (FIOH): prevention and detection of asbestos-related diseases, 1987-2005. Am. J. Ind. Med. 2006, 49:215-220.
3. Vorobiof D.A., Mafafo K. Malignant pleural mesothelioma: medical treatment update. Clin. Lung Cancer 2009, 10:112-117.
4. Vale W., Wiater E., Gray P., Harrison C., Bilezikjian L., Choe S. Activins and inhibins and their signaling. Ann. N. Y. Acad. Sci. 2004, 1038:142-147.
5. Antsiferova M., Werner S. The bright and the dark sides of activin in wound healing and cancer. J. Cell Sci. 2012, 125:3929-3937.
6. Panopoulou E., Murphy C., Rasmussen H., Bagli E., Rofstad E.K., Fotsis T. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res. 2005, 65:1877-1886.
7. Hedger M.P., de Kretser D.M. The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 2013, 24:285-295.
8. Hoda M.A., Munzker J., Ghanim B., Schelch K., Klikovits T., Laszlo V., Sahin E., Bedeir A., Lackner A., Dome B., Setinek U., Filipits M., Eisenbauer M., Kenessey I., Torok S., Garay T., Hegedus B., Catania A., Taghavi S., Klepetko W., Berger W., Grusch M. Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br. J. Cancer 2012, 107:1978-1986.
9. Walton K.L., Makanji Y., Harrison C.A. New insights into the mechanisms of activin action and inhibition. Mol. Cell. Endocrinol. 2012, 359:2-12.
10. Schneyer A., Sidis Y., Xia Y., Saito S., del Re E., Lin H.Y., Keutmann H. Differential actions of follistatin and follistatin-like 3. Mol. Cell. Endocrinol. 2004, 225:25-28.
11. Tsuchida K., Arai K.Y., Kuramoto Y., Yamakawa N., Hasegawa Y., Sugino H. Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-β family. J. Biol. Chem. 2000, 275:40788-40796.
12. Itoh S., Itoh F., Goumans M.J., Ten Dijke P. Signaling of transforming growth factor-β family members through Smad proteins. Eur. J. Biochem. 2000, 267:6954-6967.
13. Bernard D.J., Lee K.B., Santos M.M. Activin B can signal through both ALK4 and ALK7 in gonadotrope cells. Reprod. Biol. Endocrinol. 2006, 4:52.
14. Tsuchida K., Nakatani M., Yamakawa N., Hashimoto O., Hasegawa Y., Sugino H. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol. Cell. Endocrinol. 2004, 220:59-65.
15. Besson-Fournier C., Latour C., Kautz L., Bertrand J., Ganz T., Roth M.P., Coppin H. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood 2012, 120:431-439.
16. Moustakas A., Heldin C.H. Non-Smad TGF-β signals. J. Cell Sci. 2005, 118:3573-3584.
17. Huang H.M., Chang T.W., Liu J.C. Basic fibroblast growth factor antagonizes activin A-mediated growth inhibition and hemoglobin synthesis in K562 cells by activating ERK1/2 and deactivating p38 MAP kinase. Biochem. Biophys. Res. Commun. 2004, 320:1247-1252.
18. Zhang L., Deng M., Parthasarathy R., Wang L., Mongan M., Molkentin J.D., Zheng Y., Xia Y. MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration. Mol. Cell. Biol. 2005, 25:60-65.
19. Zhang M., Liu N.Y., Wang X.E., Chen Y.H., Li Q.L., Lu K.R., Sun L., Jia Q., Zhang L. Activin B promotes epithelial wound healing in vivo through RhoA-JNK signaling pathway. PLoS One 2011, 6:e25143.
20. Zhang M., Sun L., Wang X., Chen S., Jia Q., Liu N., Chen Y., Kong Y., Zhang L., Zhang A.L. Activin B promotes BM-MSC-mediated cutaneous wound healing by regulating cell migration via the JNK-ERK signaling pathway. Cell Transplant. 2014, 23:1061-1073.
21. Thompson T.B., Cook R.W., Chapman S.C., Jardetzky T.S., Woodruff T.K. Beta A versus beta B: is it merely a matter of expression?. Mol. Cell. Endocrinol. 2004, 225:9-17.
22. Hulmi J.J., Oliveira B.M., Silvennoinen M., Hoogaars W.M., Ma H., Pierre P., Pasternack A., Kainulainen H., Ritvos O. Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. Am. J. Physiol. Endocrinol. Metab. 2013, 304:E41-E50.
23. Leppäranta O., Sens C., Salmenkivi K., Kinnula V.L., Keski-Oja J., Myllärniemi M., Koli K. Regulation of TGF-β storage and activation in the human idiopathic pulmonary fibrosis lung. Cell Tissue Res. 2012, 348:491-503.
24. Ke Y., Reddel R.R., Gerwin B.I., Reddel H.K., Somers A.N., McMenamin M.G., LaVeck M.A., Stahel R.A., Lechner J.F., Harris C.C. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am. J. Pathol. 1989, 134:979-991.
25. Tamminen J.A., Parviainen V., Rönty M., Wohl A.P., Murray L., Joenväära S., Varjosalo M., Leppäranta O., Ritvos O., Sengle G., Renkonen R., Myllärniemi M., Koli K. Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis 2013, 2:e66.
26. Tamminen J.A., Myllärniemi M., Hyytiäinen M., Keski-Oja J., Koli K. Asbestos exposure induces alveolar epithelial cell plasticity through MAPK/Erk signaling. J. Cell. Biochem. 2012, 113:2234-2247.
27. Apostolou E., Stavropoulos A., Sountoulidis A., Xirakia C., Giaglis S., Protopapadakis E., Ritis K., Mentzelopoulos S., Pasternack A., Foster M., Ritvos O., Tzelepis G.E., Andreakos E., Sideras P. Activin-A overexpression in the murine lung causes pathology that simulates acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2012, 185:382-391.
28. Wakefield L.M., Hill C.S. Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat. Rev. Cancer 2013, 13:328-341.
29. de Caestecker M.P., Piek E., Roberts A.B. Role of transforming growth factor-β signaling in cancer. J. Natl. Cancer Inst. 2000, 92:1388-1402.
30. Drabsch Y., ten Dijke P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012, 31:553-568.
31. Zhang Q., Yu N., Lee C. Mysteries of TGF-beta paradox in benign and malignant cells. Front. Oncol. 2014, 4:94.
32. Tsuchida K., Nakatani M., Uezumi A., Murakami T., Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr. J. 2008, 55:11-21.
33. Quail D.F., Siegers G.M., Jewer M., Postovit L.M. Nodal signalling in embryogenesis and tumourigenesis. Int. J. Biochem. Cell Biol. 2013, 45:885-898.
34. Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y., Hasegawa Y., Bader S.A., Gazdar A.F., Minna J.D., Hida T., Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001, 20:4249-4257.
35. Abutaily A.S., Collins J.E., Roche W.R. Cadherins, catenins and APC in pleural malignant mesothelioma. J. Pathol. 2003, 201:355-362.
36. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 2013, 34:1413-1419.
37. Chen Y.G., Lui H.M., Lin S.L., Lee J.M., Ying S.Y. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp. Biol. Med. (Maywood) 2002, 227:75-87.
38. Ten Dijke P., Goumans M.J., Itoh F., Itoh S. Regulation of cell proliferation by Smad proteins. J. Cell. Physiol. 2002, 191:1-16.
39. Vehviläinen P., Koli K., Myllärniemi M., Lindholm P., Soini Y., Salmenkivi K., Kinnula V.L., Keski-Oja J. Latent TGF-β binding proteins (LTBPs) 1 and 3 differentially regulate transforming growth factor-β activity in malignant mesothelioma. Hum. Pathol. 2011, 42:269-278.
40. Deng M., Chen W.L., Takatori A., Peng Z., Zhang L., Mongan M., Parthasarathy R., Sartor M., Miller M., Yang J., Su B., Kao W.W., Xia Y. A role for the mitogen-activated protein kinase kinase kinase 1 in epithelial wound healing. Mol. Biol. Cell 2006, 17:3446-3455.
41. Ashcroft G.S., Yang X., Glick A.B., Weinstein M., Letterio J.L., Mizel D.E., Anzano M., Greenwell-Wild T., Wahl S.M., Deng C., Roberts A.B. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat. Cell Biol. 1999, 1:260-266.
42. Klein E.A., Assoian R.K. Transcriptional regulation of the cyclin D1 gene at a glance. J. Cell Sci. 2008, 121:3853-3857.
43. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 2007:1263-1284.
44. de Melo M., Gerbase M.W., Curran J., Pache J.C. Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma. J. Histochem. Cytochem. 2006, 54:855-861.
45. Shukla A., Hillegass J.M., MacPherson M.B., Beuschel S.L., Vacek P.M., Pass H.I., Carbone M., Testa J.R., Mossman B.T. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol. Cancer 2010, 9:314.
46. Marek L.A., Hinz T.K., von Massenhausen A., Olszewski K.A., Kleczko E.K., Boehm D., Weiser-Evans M.C., Nemenoff R.A., Hoffmann H., Warth A., Gozgit J.M., Perner S., Heasley L.E. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol. Cancer Res. 2014, 12:1460-1469.
47. Halder S.K., Cho Y.J., Datta A., Anumanthan G., Ham A.J., Carbone D.P., Datta P.K. Elucidating the mechanism of regulation of transforming growth factor β Type II receptor expression in human lung cancer cell lines. Neoplasia 2011, 13:912-922.
48. Heikkinen P.T., Nummela M., Leivonen S.-K., Westermarck J., Hill C.S., Kähäri V.-M., Jaakkola P.M. Hypoxia-activated Smad3-specific dephosphorylation by PP2A. J. Biol. Chem. 2010, 6:3740-3749.